Sirukumab Explained

Sirukumab (INN, USAN) (developmental code name CNTO-136, tentative brand name Plivensia) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.^[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).^[2]

Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor.

Clinical trials

Rheumatoid arthritis

It has started clinical trials. and reported some phase II results.^[3]

In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.^[4] By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.^[5]

Research

The drug was previously under development for the treatment of depression.^[6]

Notes and References

1. Web site: Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab. American Medical Association.
2. Bartoli F, Bae S, Cometi L, Matucci Cerinic M, Furst DE . Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018 . Expert Review of Clinical Immunology . 14 . 7 . 539–547 . July 2018 . 29925278 . 10.1080/1744666X.2018.1487291 . 49330982 .
3. Web site: Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis . PR News Wire . Cision . 25 May 2011 .
4. Web site: House DW . Glaxo says top-line results positive in late-stage study of sirukumab in rheumatoid arthritis . Seeking Alpha . 16 December 2015 .
5. Web site: IL-6 in RA: What Predicts Non-Progression? - High-risk patients showed most benefit with sirukumab . January 2017 .
6. Web site: Sirukumab - Janssen Biotech . AdisInsight . Springer Nature Switzerland AG .